Speed saves lives.

Every day matters when biological threats emerge, and diagnostics, therapeutics, and vaccines are needed in the field. Traditional approaches take time, and mRNA (while fast) can’t match the simplicity, stability, and cost-effectiveness of proteins.

Boost is building a future that accelerates the creation of diagnostics, therapeutics, and vaccines. We do this by creating Rapid Antigen Deployment (RAD™) frameworks that enable production of protein subunit antigens in 14 days or less. Boost’s RAD™ antigens are targeted, stable, scalable, and readily updatable to address emerging and evolving infectious disease threats in record time. NIH/NIAID and CEPI support our work.

Boost’s RAD™ antigens can be used to make safe vaccines — the subject of two NIH-sponsored Phase 1 clinical trials — and to generate monoclonal antibodies (mAbs). These mAbs power diagnostics for early detection, and therapeutics for effective treatment. Our goal is to deliver lifesaving products to the field in record time.